Publications list

Antonia Morga, DPhil, Nicholas R. Latimer, PhD, Martin Scott, MSc, Neil Hawkins, PhD, CStat, Michael Schlichting, MSc, Jixian Wang, PhD, Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework? Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum. Value in Health, September 20, 2022

Jonathan C Alsop
& Lawrence O Pont, Matching-adjusted indirect comparison via a polynomial-based non-linear optimisation method. Journal of Comparative Effectiveness Research, 4 May 2022,

Dürr, H.-P.
, Eichner, M.: „Corona-Pandemie: Zukunfts-Überlegungen aus der Sicht epi- demiologischer Modellierung“ in: „Monitor Versorgungsforschung“ (02/22), S. 57-63.

Anja Scholzen, Margot de Vries,
Hans-Peter Duerr, Hendrik-Jan Roest, Ann E. Sluder, MArk C. Poznansky, Milou L.C.E. Kouwijzer, Anja Garritsen, Whole Blood Interferon γ Release Is a More Sensitive Marker of Prior Exposure to Coxiella burnetii Than Are Antibody Responses. Frontiers in Immunology, 28 July 2021 |

Jonathan Alsop, PhD, Numerus Ltd, Wokingham, England, United Kingdom; Nicholas Latimer, MSc, PhD, ScHARR, University of Sheffield, Sheffield, England, United Kingdom; Melvin (Skip) Olson, PhD, Novartis Pharma AG, Basel, Switzerland; Daniel Rosenberg, PhD, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; and Martin Scott, MSc, Numerus GmbH, Tübingen, Germany. Estimating Comparative Effectiveness When Patients Are Switching Treatments: A Real-World Challenge, Value & Outcomes Spotlight March/April 2020 p 31—33

Hans-Peter Dürr PhD
, Martin Scott MSc, Moderne Ergebnisvisualisierung anstelle von Mammut-Dossiers! (Modern visualization of results instead of mammoth dossiers!) market access & health policy January 2020

Alsop J. and Pont L., 2018. Comparing Ophthalmology Treatments Via The Integration Of IPD And Aggregate-Level Data: Which Matching Adjusted Indirect Comparison (MAIC) Approach Is Best? [Poster]. [online] Available at:

Jonathan Alsop PhD, Martin Scott MSc, Estimands—What Do They Mean for Health Technology Assessment? Value & Outcomes Spotlight September/October 2018

Marie Miglianico, Maarten Eldering, Hannah Slater, Neil Ferguson, Pauline Ambrose, Rosemary S. Lees, Karin M. J. Koolen, Katerina Pruzinova, Magdalena Jancarova, Petr Volf, Constantianus J. M. Koenraadt, Hans-Peter Duerr, Graham Trevitt, Baiyuan Yang, Arnab K. Chatterjee, John Wisler, Angelika Sturm, Teun Bousema, Robert W. Sauerwein, Peter G. Schultz, Matthew S. Tremblay, and Koen J. Dechering. Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases. Proceedings of the National Academy of Sciences Jul 2018, 201801338; DOI:10.1073/pnas.1801338115

Dechering KJ, Duerr HP, Koolen KMJ, et al., 2017. Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission. Sci Rep 7: 17680.

Alsop J, Medin J, Cornelissen C, Vormfelde SV, Ziemssen T (2017) Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLoS ONE 12(5): e0173353.

Bell, Katy J. L. PhD; Hayen, Andrew PhD; Glasziou, Paul PhD; Mitchell, Andrew S. MMedSci; Farris, Maria BSc; Wright, Jonathan MSc; Duerr, Hans-Peter PhD; Mitchell, Paul PhD; Irwig, Les PhD Early CRT Monitoring using time-domain optical coherence Tomography does not add to visual acuity for predicting visual loss in patients with Central retina vein occlusion treated with intravitreal Ranibizumab. Secondary Analysis of Trial Data 2017. RETINA: March 2017 - Volume 37 - Issue 3 - p 509–514

Regnier SA, Alsop J, Wright J, Nixon R, Staines H, Fajnkuchen F. Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):793-801

Alessandro Crotta, Christopher Keir, Julie Cleret, Simu K. Thomas, Linda Armstrong. Disease Characteristics and Overall Survival in Pediatric Patients with Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia after Stem Cell Transplantation. Abstract for BMT published Dec 2016

Jonathan Alsop, Martin Scott, William Archey. The mixed randomized trial: combining randomized, pragmatic and observational clinical trial designs. J Comp Eff Res. 2016 Nov;5(6):569-579

Fókás L, Hyperbolic Discounting of Effects in Economic Evaluations. Value in Health, November 01, 2016. DOI:

Sobha Sivaprasad, Stephane A. Regnier, Franck Fajnkuchen, Jonathan Wright, Alan R. Berger, Paul Mitchell, Michael Larsen. Using Patient-Level Data to Develop Meaningful Cross-Trial Comparisons of Visual Impairment in Individuals with Diabetic Macular Oedema. Adv Ther. 2016; 33: 597–609

Mitchell P., Pont, L., Margaron, P. and Chong, V., 2016. Predictors Of =20/40 Vision With Ranibizumab Treatment In Patients With Diabetic Macular Edema: A Post-Hoc Analysis Of The RESTORE Study. [Oral]. EURETINA European Congress, 2016. Copenhagen, Denmark

Sebastian M. Waldstein, MD, Jonathan Wright, MSc, James Warburton, MBBS, Philippe Margaron, PhD, Christian Simader, MD, MSc, Ursula Schmidt-Erfurth, MD. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 2016 Jan;123(1):60-9

Jonathan Alsop, Christian Cornelissen, Stefan Viktor Vormfelde, Jennie Medin, Tjalf Ziemssen. Confirmed disability improvement in patients with active multiple sclerosis treated with fingolimod versus BRACE therapies: a matched comparison of treatments from the PANGAEA and PEARL registry studies. ISPOR November 2015

Hans-Peter Duerr, Jonathan Alsop, Niklas Bergvall, Christian Cornelissen, Stefan Viktor Vormfelde and Tjalf Ziemssen. Time Off From Work: a Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies (P7.019). ePoster presentation at the American Academy of Neurology 67th Annual Meeting, 18–25 April 2015

Duerr, H. P., Duerr-Aguilar, Y., Andritzky, W., Camps, A., Deegener,G., Dum, C., Godinho, F., Li, L., Rudolph, J., Schlottke, P., Hautzinger,M. Loss of Child Well-Being: A Concept for the Metrics of Neglect and Abuse Under Separation and Divorce. Child Ind Res (2015) 8: 867

Duerr HP, Alsop J, Bergvall N, Cornelissen C, Vormfelde S V, Moser S, Fuchs A, Schwarz HJ, Ziemssen T. Effectiveness of fingolimod compared with interferons and glatiramer acetate for the treatment of multiple sclerosis: a matched comparison of treatments from the PANGAEA and PEARL studies. Neurowoche 2014, 15–19 September 2014, Munich, Germany

Stephane Regnier, William Malcolm, Felicity Allen, Jonathan Wright, Vladimir Bezlyak. Efficacy of Anti-VEGF and Laser Photocoagulation in the Treatment of Visual Impairment due to Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis. PLoS One. 2014 Jul 16;9(7):e102309

Patterson, M.C.; Mengel, E.; Wijburg, F.A.; Vanier, M.T.; Schwierin, B.; Muller, A.; Drevon, H.; Pineda, M. Longitudinal data from the international registry for Niemann-Pick disease type C (NPC). Molecular Genetics and Metabolism, Volume 111, issue 2 (February, 2014), p. S85. ISSN: 1096-7192 DOI: 10.1016/j.ymgme.2013.12.203 Elsevier Science

Stauch A, Duerr HP, Picado A, Ostyn B, Sundar S, Rijal S, et al. Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. PLoS Neglected Tropical Diseases. 2014;8(4):e2810.

Regnier S, Alsop J. Poster : POS-1939 - Efficacy comparison of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema- a systematic review and network meta-analysis. 14th EURETINA Congress London 2014 - Poster submission

Guillevin L, Hunsche E, Denton C P, Krieg T, Schwierin B, Rosenberg D, Matucci-Cerinic M for the DUO Registry Group, 2013. Silkey M, Actelion Pharmaceuticals Ltd. Palmer M, Numerus Ltd.Patterson M C, Mengel E, Wijburg F A, Muller A, Schwierin B, Drevon D,Vanier M T and Pineda M Orphanet Journal of Rare Diseases 2013, 8:12,

Bergvall N, Rathi H, Nixon R M, Thom H H Z, Alsop J, Dunsire L. Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression. Value in Health, Volume 16, Issue 7 , Page A619, November 2013

Jaffer U, John NW, Standfield N. Surgical Trainee Opinions in the United Kingdom Regarding a Three Dimensional Virtual Mentoring Environment (MentorSL) in Second Life: Pilot Study Alsop J (statistical support). JMIR Serious Games 2013| vol.1|iss.1|e2|p.6

Chong V, Amoaku W, Alsop J and Osborne A. Effectiveness of quarterly (Q3M) versus monthly (QM) ranibizumab according to initial gains in visual acuity - an analysis of 12 month data from the EXCITE study. Invest Ophthalmol Vis Sci 2013;54: E-Abstract 3816., ARVO 2013

Bergvall N, Sfikas N, Chin P, Tomic D, von Rosenstiel P, Alsop J, Cutter G, Calabresi P, Jeffery D, Lublin F, Kappos L. Poster P04.128 Effects of Fingolimod on Disability Progression in Patients with Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II. Scientific Abstract Listing and Annual Meeting Information, February 12 2013

Bergvall, N.; Rathi, H.; Nixon, R.M.; Thom, H.H.Z.; Alsop, J.; Dunsire, L. Modeling the Impact of Disease Modifying Treatment on Time to Disability Health States in Multiple Sclerosis: An Evaluation of Oral Therapies Through Indirect Comparisons of 6-Month Confirmed Disability Progression. Value in Health, Volume 16, issue 7 (November, 2013), p. A619. ISSN: 1098-3015 DOI: 10.1016/j.jval.2013.08.1804

Thibault F, Dromain C, Breucq C, Balleyguier CS, Malhaire C, Steyaert L, Tardivon A, Baldan E, Drevon H. Digital breast tomosynthesis versus mammography and breast ultrasound: a multireader performance study. European Scociety of Radiology (2013) 23:2441–2449, DOI 10.1007/s00330-013-2863-5

Lee W-T N, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ and Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J 2012 40:604-611; published ahead of print 2012.

Patterson, M.; Pineda, M.; Mengel, E.; Wijburg, F.; Vanier, M.; Schwierin, B.; Muller, A.; Alsop, J.; Wraith, E. Update From the International Registry for Niemann-Pick Disease Type C (NP-C) in Clinical Practice. Molecular Genetics and Metabolism, Volume 105, issue 2 (February, 2012), p. S51. ISSN: 1096-7192 DOI: 10.1016/j.ymgme.2011.11.129 Elsevier Science

Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M. Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India. PLoS Neglected Tropical Diseases. 2012;6(12):e1973.

Watson L, Wilson B P, Alsop J and Kumar S.Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Article first published online: 26 JUL 2011 DOI: 10.1111/j.1463- 1326.2011.01413.x © 2011 Blackwell Publishing Ltd, Diabetes, Obesity and MetabolismVolume 13, Issue 9, pages 823–831, September 2011

Duerr HP, Raddatz G, Eichner M. Control of onchocerciasis in Africa: Threshold shifts, breakpoints and rules for elimination. International Journal for Parasitology. 2011;41:581–589.

Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Duerr HP. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Neglected Tropical Diseases. 2011;5(11):e1405. Epub 6 June 2011.

Alsop J, Scott M. Numerous Predictions for the Future of Clinical Trial Development. CRfocus, Volume 21, Number 8 (Dec 2010 /Jan 2011) ISSN: 0968-0594

Duerr HP, Eichner M. Epidemiology and control of onchocerciasis: the threshold biting rate of savannah onchocerciasis in Africa. International Journal for Parasitology. 2010;40(6):641-650. Epub 28 November 2009

Eichner M, Schwehm M, Duerr HP, Witschi M, Koch D, Brockmann SO, et al. Antiviral prophylaxis during pandemic influenza may increase drug resistance. BMC Infectious Diseases. 2009;9:4. Epub 22 January 2009

Krumkamp R, Duerr HP, Reintjes R, Ahmad A, Kassen A, Eichner M. Impact of public health interventions in controlling the spread of SARS: modelling of intervention scenarios. Int J Hyg Environ Health. 2009;212(1):67-75. Epub 9 May 2008.

Mikolajczyk R, Krumkamp R, Bornemann R, Ahmad A, Schwehm M, Duerr HP. Influenza – Einsichten aus mathematischer Modellierung. Deutsches Ärzteblatt. 2009;106(47):777–782.

Vidondo B, Oberreich J, Brockmann SO, Duerr HP, Schwehm M, Eichner M. Effects of interventions on the demand for hospital services in an influenza pandemic: a sensitivity analysis. Swiss Med Wkly. 2009;139(35-36):505-510. Epub 14 August 2009

Brockmann SO, Schwehm M, Duerr HP, Witschi M, Koch D, Vidondo B, et al. Modeling the effects of drug resistant influenza virus in a pandemic. Virol J. 2008;5:133. Epub 1 November 2008

Duerr HP, Hoffmann WH, Eichner M. Does resistance to filarial reinfections become leaky over time? Trends in Parasitology. 2008;24:350-354.

Duerr HP, Raddatz G, Eichner M. Diagnostic value of nodule palpation in onchocerciasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(2):148-154.